Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Iovance Biotherapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Iovance Biotherapeutics, Inc.’s stock price such as:

• Iovance Biotherapeutics, Inc.’s current stock price and volume
• Why Iovance Biotherapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for IOVA from analysts
• IOVA’s stock price momentum as measured by its relative strength

About Iovance Biotherapeutics, Inc. (IOVA)

Before we jump into Iovance Biotherapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Want to learn more about Iovance Biotherapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Iovance Biotherapeutics, Inc..

Iovance Biotherapeutics, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Iovance Biotherapeutics, Inc.’s stock price was $4.070.

Iovance Biotherapeutics, Inc. is down 13.22% from its previous closing price of $4.690.

During the last market session, Iovance Biotherapeutics, Inc.’s stock traded between $4.020 and $4.550. Currently, there are approximately 418.51 million shares outstanding for Iovance Biotherapeutics, Inc..

Iovance Biotherapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Iovance Biotherapeutics, Inc. Stock Price History

Iovance Biotherapeutics, Inc.’s (IOVA) price is currently down 2.16% so far this month.

During the month of July, Iovance Biotherapeutics, Inc.’s stock price has reached a high of $5.640 and a low of $3.760.

Over the last year, Iovance Biotherapeutics, Inc. has hit prices as high as $5.640 and as low as $1.760. Year to date, Iovance Biotherapeutics, Inc.’s stock is up 49.08%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Iovance Biotherapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there were 0 analysts who downgraded Iovance Biotherapeutics, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Iovance Biotherapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Iovance Biotherapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Iovance Biotherapeutics, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Iovance Biotherapeutics, Inc. (IOVA) by visiting AAII Stock Evaluator.

Relative Price Strength of Iovance Biotherapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Iovance Biotherapeutics, Inc. has a weighted four-quarter relative price strength of 11.45%, which translates to a Momentum Score of 84 and is considered to be Very Strong.

Want to learn more about how Iovance Biotherapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Iovance Biotherapeutics, Inc. Stock Price: Bottom Line

As of July 31, 2026, Iovance Biotherapeutics, Inc.’s stock price is $4.070, which is down 13.22% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Iovance Biotherapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.